CRISPR Therapeutics
CRSPMarket price data through November 12, 2026.
Performance
Nov 2021 – Nov 2026
Track record
How this pick has done since Benson first called it.
- Benson Return
- -24%
- How much this stock is up since Benson first picked it — measured from the price at the time of that first pick, not from today.
- First pick price
- ~$56
- Roughly what one share cost when Benson first picked this stock. This is the starting line for the Benson Return.
- Tracking since
- April 2026
- The month this stock first became a Benson pick.
- Tracking duration
- 6 months
- How long Benson has been tracking this pick.
About CRISPR Therapeutics
CRISPR Therapeutics uses molecular scissors, based on Nobel Prize winning science, to fix the typos in DNA that cause serious diseases. Its first approved product, Casgevy, is a one time treatment that frees most sickle cell and beta thalassemia patients from painful attacks and endless blood transfusions. Now it is aiming the same idea at much bigger targets like high cholesterol, hoping a single treatment could someday replace a lifetime of daily pills.
The case for and against
Both sides of the story, in plain English.
- Sales Surging
Casgevy brought in 99 million dollars this quarter. That is up 30 percent from just three months earlier and nearly six times what it made a year ago. More than 750 patients worldwide have now started treatment. It is approved in 39 countries, and five of them now cover younger children, some as young as two, with the U.K., the United Arab Emirates, and Bahrain joining recently.
- Heart Health Hope
The next big bet is a one time treatment for high cholesterol and high blood fats, two major drivers of heart attacks. In early testing, the top dose cut bad cholesterol by 53 percent and blood fats by 48 percent, and the results held for a full year. The FDA just gave it two special fast lane designations, and new results come out at a major heart conference on November 9.
- Sharing Profits
CRISPR does not own its blockbuster outright. Partner Vertex makes and sells Casgevy and keeps 60 percent of the profits, leaving CRISPR with 40 percent. The partnership cost CRISPR 41 million dollars this quarter, down from 57 million a year ago as sales grew, but a big slice of the upside still goes to the partner.
- Losses Linger
Even with sales rising, the company lost 111 million dollars this quarter. That is more than the 106 million it lost a year ago and up from 91 million last quarter, because research spending jumped 22 percent to 72 million dollars. It has about 2.3 billion dollars in the bank, but roughly 585 million of that was borrowed earlier this year. Almost everything besides Casgevy is still in early human testing, where many experiments fail.
Other companies we track
How to read this page
This automated research summary uses Financial Modeling Prep market data through 2026-11-12. Model signals, scores, and risk labels can change and may be incomplete or wrong.
Want Benson to watch CRSP for you?
Get the app to follow every Benson pick live — and let Benson do the research for you.